Cabozantinib in Advanced Hepatocellular Carcinoma: Efficacy and Safety Data from an International Multicenter Real-Life Cohort

MLA

Finkelmeier, Fabian, et al. “Cabozantinib in Advanced Hepatocellular Carcinoma: Efficacy and Safety Data from an International Multicenter Real-Life Cohort.” Liver Cancer, vol. 10, no. 4, July 2021, pp. 360–69. EBSCOhost, https://doi.org/10.1159/000515490.

APA

Finkelmeier, F., Scheiner, B., Leyh, C., Best, J., Fründt, T. W., Czauderna, C., Beutel, A., Bettinger, D., Weiß, J., Meischl, T., Kütting, F., Waldschmidt, D.-T., Radu, P., Schultheiß, M., Peiffer, K.-H., Ettrich, T. J., Weinmann, A., Wege, H., Venerito, M., … Waidmann, O. (2021). Cabozantinib in Advanced Hepatocellular Carcinoma: Efficacy and Safety Data from an International Multicenter Real-Life Cohort. Liver Cancer, 10(4), 360–369. https://doi.org/10.1159/000515490

Chicago

Finkelmeier, Fabian, Bernhard Scheiner, Catherine Leyh, Jan Best, Thorben Wilhelm Fründt, Carolin Czauderna, Alica Beutel, et al. 2021. “Cabozantinib in Advanced Hepatocellular Carcinoma: Efficacy and Safety Data from an International Multicenter Real-Life Cohort.” Liver Cancer 10 (4): 360–69. doi:10.1159/000515490.